Why MOTS-c Is Biologically Unique: A Peptide Encoded in Mitochondrial DNA
Nearly all human proteins and peptides are encoded by genes inside the cell's nucleus. Mitochondria—the organelles responsible for generating cellular ATP—also carry their own small circular mitochondrial genome.
Research published in Cell Metabolism examined MOTS-c and metabolic homeostasis, obesity, and insulin resistance in animal models.
How MOTS-c Works: The Folate–AICAR–AMPK Cascade & Nuclear Translocation
| Step in the Cascade | Biochemical Mechanism | Key Citation |
|---|---|---|
| 1. Folate-Methionine Cycle Inhibition | MOTS-c inhibits the folate-methionine cycle, temporarily blocking de novo purine biosynthesis. | Cell Metabolism |
| 2. Endogenous AICAR Accumulation | Purine pathway blockade causes intracellular levels of endogenous AICAR (an AMPK-activating intermediate) to accumulate in cultured cells. | Cell Metabolism |
| 3. AMPK Activation & Glucose Uptake | Elevated AICAR activates AMP-activated protein kinase (AMPK), stimulating fatty-acid oxidation and promoting glucose uptake in skeletal muscle. | Cell Metabolism |
| 4. Stress-Induced Nuclear Translocation | Under metabolic stress, MOTS-c moves to the nucleus and regulates stress-adaptation genes. | Not cited |
Exercise Physiology & Aging Research
In a study published in Nature Communications and subsequent translational reviews in the Journal of Translational Medicine, researchers examined endogenous MOTS-c signaling during exercise and aging:
- Human Exercise Response: Exercise increases endogenous MOTS-c expression in human skeletal muscle and circulation (Nature Communications).
- Aged Mouse Research: MOTS-c treatment was reported to reverse age-related skeletal muscle insulin resistance and improve physical capacity in aged mice (Journal of Translational Medicine).
- Clinical Translation Boundary: While a synthetic analogue of MOTS-c (developmental code CB4211) entered early Phase Ia human safety testing for non-alcoholic steatohepatitis (NASH) and obesity, unmodified MOTS-c itself has not completed Phase II/III human clinical efficacy trials.
Regulatory Status (April 2026) & WADA Prohibition
On the U.S. FDA's Section 503A Bulk Drug Substances list current as of April 22, 2026, MOTS-c was nominated for Category 2, and that nomination was subsequently withdrawn. MOTS-c is not an FDA-approved drug and does not appear on Category 1; it is included in HHS's draft published October 30, 2026 describing when the agency intends to forgo enforcement over qualifying single-ingredient prescription compounding.
In competitive athletics, the World Anti-Doping Agency (WADA) explicitly added MOTS-c to the Prohibited List under Section S4.4 (Metabolic Modulators — AMP-activated protein kinase [AMPK] activators), banning it at all times in and out of competition.
Scientific References and Further Reading
- Cell Metabolism — MOTS-c, metabolic homeostasis, obesity and insulin resistance
- Human exercise and endogenous MOTS-c expression (Nature Communications)
- MOTS-c and age-related skeletal muscle insulin resistance (Journal of Translational Medicine)